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Short Report: Metabolism
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Abstract
Aim To investigate glucose and insulin metabolism in participants with ataxia telangiectasia in the absence of a
diagnosis of diabetes.
Methods A standard oral glucose tolerance test was performed in participants with ataxia telangiectasia (n = 10) and
in a control cohort (n = 10). Serial glucose and insulin measurements were taken to permit cohort comparisons of
glucose-insulin homeostasis and indices of insulin secretion and sensitivity.
Results During the oral glucose tolerance test, the 2-h glucose (6.75 vs 4.93 mmol/l; P = 0.029), insulin concentrations
(285.6 vs 148.5 pmol/l; P = 0.043), incremental area under the curve for glucose (314 vs 161 mmol/l/min; P = 0.036)
and incremental area under the curve for insulin (37,720 vs 18,080 pmol/l/min; P = 0.03) were higher in participants
with ataxia telangiectasia than in the controls. There were no significant differences between groups in fasting glucose,
insulin concentrations or insulinogenic index measurement (0.94 vs 0.95; P = 0.95). The Matsuda index, reflecting
whole-body insulin sensitivity, was lower in participants with ataxia telangiectasia (5.96 vs 11.03; P = 0.019) than in
control subjects.
Conclusions Mutations in Ataxia Telangiectasia Mutated (ATM) that cause ataxia telangiectasia are associated with
elevated glycaemia and low insulin sensitivity in participants without diabetes. This indicates a role of ATM in glucose
and insulin metabolic pathways.
Diabet. Med. 33, 371–375 (2016)
Introduction
The anti-hyperglycaemic agent, metformin, is recommended
as thefirst-lineoral therapy for the treatmentofType2diabetes
in both national and international guidelines; however, despite
being widely prescribed for >50 years, the mechanisms
underpinning metformin’s actions and the considerable vari-
ation in response to this drug are only now emerging [1,2].
Recently, we reported in a genome-wide study an associ-
ation between the single-nucleotide polymorphism (SNP)
rs11212617 and metformin glycaemic response [3]. This
SNP is located on chromosome 11 within a large linkage
disequilibrium block that includes a total of seven potential
candidate genes. As with any genome-wide association study,
additional functional, mouse and human studies are required
to confirm the metformin response variant at this locus.
A potential causal gene responsible for this relationship is
Ataxia Telangiectasia Mutated (ATM), a serine/threonine
protein kinase with a central role in the cellular response to
DNA damage [4]. Although this cancer gene has not
previously been reported to be associated with metformin
action, there is growing evidence of the role of ATM in
glucose metabolism.
It has been shown that ATM-deficient mice exhibit glucose
intolerance, insulin resistance and impaired insulin secretion
[5,6], while interactions of this protein kinase with multiple
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components of insulin signalling (JNK, PI3K, IRS2 and AKT)
have been observed in in vitro studies [7]. Furthermore, case
reports from the 1970s in a limited number of participants
with diabetes and loss of functional ATM mutations,
resulting in the autosomal recessive condition ataxia telang-
iectasia, showed marked insulin resistance [8].
Given these previous case reports of insulin resistance in
ataxia telangiectasia, and the novel finding that ATM may
influence metformin response, we aimed to investigate
glucose metabolism in participants with ataxia telangiectasia
in the absence of a diagnosis of diabetes.
Participants and methods
Participants
Participants with ataxia telangiectasia (n = 10) were recruited
from the National Adult Ataxia Telangiectasia Centre, Pap-
worth Hospital, in collaboration with the Ataxia Telangiec-
tasia Society. Participants with ataxia telangiectasia were aged
>16 years, non-pregnant and formally diagnosed with ataxia
telangiectasia. The control subjects (n = 10) were identified
from the UK Type 2 Diabetes Case Control collection study
and were matched for age, sex and BMI. All participants were
white. This study was granted ethical approval by the East of
Scotland Research Ethics Committee and informed consent
was obtained from all participants.
Methods
The study participants attended Papworth Hospital, Cam-
bridge or Ninewells Hospital, Dundee. Participants fasted
overnight and underwent a standard 75-g oral glucose
tolerance test (OGTT). Glucose and insulin samples were
collected in fluoride and lithium-heparin tubes respectively at
0, 30, 60, 90 and 120 min. Samples were centrifuged
immediately and stored at 80°C. Glucose concentrations
were analysed using the hexokinase method with Siemens
ADVIA 2400 (Siemens Healthcare Diagnostics Inc, Tarry-
town, NY, USA). Insulin was measured using the Auto-
DELFIA assay (PerkinElmer, Waltham, MA, USA).
Calculations
The incremental area under the curve (AUC) of plasma
glucose and insulin during the OGTT were calculated
according to the trapezoid rule and reported to the nearest
integer. Insulin secretion was evaluated by calculating the
AUC of insulin to AUC of glucose ratio (AUCins/glu). The
Matsuda index was calculated as an approximation of
composite whole-body insulin sensitivity [9]. Homeostasis
model assessment of insulin resistance (HOMA-IR) values
were calculated by dividing a multiple of fasting insulin (mU/
l) and glucose (mmol/l) concentrations by 22.5. The insulino-
genic index and homeostasis model assessment of b-cell
function (HOMA-b) were calculated as indices of b-cell
function. Insulinogenic index was calculated as Dinsulin
(mU/ml)/Dglucose (mg/dl) between 0 and 30 min, and
HOMA-b was calculated as: 20 9 fasting glucose (mmol/l)
divided by [fasting insulin (mU/l)-3.5]. When required for
calculations, glucose and insulin were converted to mg/dl and
mU/l by a conversion factor of 0.0555 and 6.0 respectively.
Statistical analysis
Analysis was performed using STATA version 10.1 (Stata
Corp., College Station, TX, USA). Our study had 80%
power (a = 0.05) to detect the observed differences in our
primary outcome, insulin sensitivity. Two-tailed unpaired
t-tests were used for comparisons between groups. Welch’s
correction was used for comparisons with unequal variances.
The Mann–Whitney U-test was used for non-parametric
data. A two-sided P value <0.05 was taken to indicate
statistical significance. Data are presented as means (SEM).
Results
Participants with ataxia telangiectasia and control partici-
pants were well matched for age, sex and BMI (Table 1). The
mean fasting glucose (Fig. 1) for participants with ataxia
telangiectasia was 4.68 mmol/l compared with 4.65 mmol/l
in control subjects (P = 0.89; 95% CI 0.42, 0.48). In
participants with ataxia telangiectasia 2-h glucose concen-
trations were 6.75 mmol/l vs 4.93 mmol/l in control subjects
(P = 0.029; 95% CI 0.21, 3.42).
Fasting insulin concentrations were 39.7 and 41.4 pmol/l
in the ataxia telangiectasia and control groups, respectively
(P = 0.87). The 2-h insulin concentrations were higher in the
ataxia telangiectasia group than in the control group (mean
difference=137.1 pmol/l; P = 0.043; 95% CI 4.4, 269.8).
Mean incremental AUC glucose was significantly higher in
the ataxia telangiectasia group compared with the control
What’s new?
• In a genome-wide association study in 2011, our group
identified Ataxia Telangiectasia Mutated (ATM) as a
potential candidate gene associated with glycaemic
response to metformin.
• In this study, we investigate the role of ATM in
carbohydrate metabolism by performing an oral glu-
cose tolerance test in participants with recessive muta-
tions in this gene, causing the condition ataxia
telangiectasia, and healthy control subjects.
• We show that ataxia telangiectasia is associated with
elevated glycaemia and decreased insulin sensitivity.
• These results indicate a significant role of ATM in
glucose and insulin metabolic pathways.
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group with a mean difference of 153 mmol/l/min (P = 0.036;
95% CI 10.73, 295.87). Mean incremental AUC insulin was
also higher in the ataxia telangiectasia group with a mean
difference of 19 640 pmol/l/min (P = 0.03; 95% CI 1997.3,
32,783.6). The AUCins/glu ratio was 132.0 in the ataxia
telangiectasia group and 159.9 in the control group, with a
mean difference of 27.9 (P = 0.19).
There were no significant differences between HOMA-b
(P = 0.56) and insulinogenic index (P = 0.95) as indices of
b-cell insulin secretion. HOMA-IR also did not differ between
the two groups (P = 0.81). The Matsuda index was higher,
however, in participants with ataxia telangiectasia than in the
control subjects (5.96 vs 11.03), with a mean difference of 5.1
(P = 0.019; 95% CI 9.13, 1.01) consistent with insulin
resistance in the ataxia telangiectasia group.
Discussion
This study supports the role of ATM mutations in abnormal
glucose tolerance. Following a 2-h OGTT, incremental AUC
glucose values were ~95% higher in participants with ataxia
telangiectasia compared with control subjects, implying
significant postprandial hyperglycaemia. Similarly, there
was a marked but appropriate increase in insulin concentra-
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FIGURE 1 Glucose (a) and insulin (b) excursions during a 2-h OGTT. Mean values  SEM for the ataxia telangectasia (solid line) and control (dashed
line) cohorts are charted. *P < 0.05.
Table 1 Participant characteristics, glucose-insulin homeostasis
variables and insulin sensitivity indices in the ataxia telangiectasia and
control cohorts
Ataxia
telangiectasia Control P
Age, years 39.4  2.7 38.9  2.3 –
Men, n (%) 4 (40) 4 (40) –
BMI, kg/m2 24.7  1.8 25.2  2.5 –
Glucose–insulin homeostasis
Incremental 2-h
glucose AUC,
mmol/l/min
314  57.3 161  36.4 0.036
Incremental 2-h
AUC insulin,
pmol/l/min
37,720  7,424 18,080  3,496 0.03
AUCins/glu ratio 132.0  107.4 159.9  97.2 0.19
Indices of insulin sensitivity and secretion
HOMA-b 64.42  73.39 112.47  67.52 0.56
Insulinogenic
index
0.94  0.13 0.95  0.12 0.95
Matsuda index 5.96  0.77 11.03  1.69 0.019
HOMA-IR 1.41  0.23 1.50  0.35 0.81
AUC, area under the curve; AUCins/glu ratio, AUC of insulin to
AUC of glucose ratio; HOMA- b, homeostasis model assess-
ment of b-cell function; HOMA-IR, homeostasis model assess-
ment of insulin resistance.
Data are expressed as means  SEM.
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tions in participants with ataxia telangiectasia after the
glucose challenge.
Interestingly, there was no difference in insulinogenic
index or HOMA-b as surrogate markers of b-cell function,
but rather a reduction in whole-body composite insulin
sensitivity. As HOMA-IR values were equivalent between
groups, such results probably represent a reduction in
peripheral, rather than hepatic, insulin sensitivity. This
observation is at odds with the relationship between ATM
and metformin response, as this drug predominantly acts on
the liver [1,2]; however, our understanding of metformin
pharmacology is ever-changing and ATM substrates may be
implicated in the wider anti-hyperglycaemic role of this drug.
The insulin excursions observed in participants with ataxia
telangiectasia in the present study were modest compared
with previous reports of participants with ataxia telangiec-
tasia and diabetes [8]. This difference may represent either a
less severe phenotype, as our participants did not have
diabetes, or the historical use of non-specific insulin radioim-
munoassays that were prone to cross-reactivity with insulin-
like molecules. Nevertheless, our results show a relative
reduction in insulin sensitivity in participants with ataxia
telangiectasia when compared with healthy participants.
People with Ataxia telangiectasia are reported to have an
increased risk of developing diabetes [10]. Our results are
consistent with this being largely mediated via an insulin-
resistant mechanism.
One weakness of the present study is that an OGTT was
undertaken rather than a euglycaemic clamp study because of
the challenges of performing the latter in physically impaired
participants.Although the indices obtained fromanOGTTare
estimates, they correlatewell with results obtained from clamp
studies [9,11]. This weakness could be addressed by perform-
ing clamp studies in obligate heterozygous parents of partic-
ipants with ataxia telangiectasia, which would also permit the
study of metformin response directly.
The dysglycaemic ataxia telangiectasia phenotype suggests
that ATM may regulate several processes important in
carbohydrate metabolism. ATM has been shown to partic-
ipate in insulin signalling via phosphorylation of elF-4E-
binding protein 1[4]. Furthermore, this kinase mediates the
full activation of AKT activity, regulates GLUT4 transloca-
tion by insulin in skeletal muscle, and may even regulate
adipocyte differentiation, which may in part explain the
postprandial dysglycaemia evident in people with ataxia
telangiectasia [12,13].
Our results are highly relevant to a number of disease
processes. People with ataxia telangiectasia and those with
germline ATM mutations are predisposed to cancer, while
somatic ATM mutations and perturbed ATM signalling
promote tumourgenesis [14]. In addition to ATM’s role in
DNA damage response, glucose restriction, as a consequence
of ATM deficiency, may be advantageous to the survival of
solid tumours through processes such as autophagy. Fur-
thermore, variation in the ATM gene has been associated
with coronary artery disease [15]. Such observations suggest
a potential role of ATM within the development of metabolic
disease, possibly through alterations in insulin metabolism
and resistance.
In summary, the present study shows that participants
possessing recessive loss of function mutations in ATM have
dysglycaemia and lower insulin sensitivity when compared
with a control cohort. This indicates that ATM has a role in
glucose and insulin metabolic pathways. Further studies are
required to characterize the mechanisms responsible for such
interactions.
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